Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Safety and Effectiveness of Warfarin, Dabigatran, and Rivaroxaban Among Japanese Patients With Non-valvular Atrial Fibrillation (NVAF) and Concomitant Coronary Artery Disease (CAD)

NCT05051904 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05051904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05051904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Safety and Effectiveness of Warfarin, Dabigatran, and Rivaroxaban Among Japanese Patients With Non-valvular Atrial Fibrillation (NVAF) and Concomitant Coronary Artery Disease (CAD)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
May 17, 2022
Completion date
July 29, 2022
Enrollment
39,357 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, coronary artery disease